Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Ended early

PROSTarget PROSTarget: Understanding the aggressive nature and key molecular drivers of metastatic dissemination in lethal PCa.

Coordinator
Fundacio Institut De Recerca Biomedica (irb Barcelona), Spain
Runs
1 July 2023 to 30 June 2025
Status
Ended early
EU funding
€165k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101108377

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer cells dissemination from primary tumors to distant sites is the most terrifying evolving process of cancer. Such an irreversible and irreparable process encompasses tumor cells escaping, extravasating into blood stream and colonizing distant sites and is known as metastasis origin. Metastases spread is the leading cause of cancer-related deaths. The scattered but aggressive nature of metastatic disease and the extensive but not striking treatment effort history of metastatic cancers represents still a major obstacle in scientific progress and curability rates stemming from translational cancer research.

Prostate cancer (PCa) hits men with high incidence and shows heterogeneity and resistance to standard of care. Altogether those hints imply that patients exhibiting disease progression, will head into complications succumbing to PCa-related high mortality, representing a major socio-economic problem world-wide. Importantly, PCa metastasis strikes after resistance acquisition to antiandrogens and taxols, overall limiting treatment efficacy.

In this context, cancer research is vital with the aim of shedding new light on causal factors, unrevealing molecular mediators of the metastatic process, responsible for treatment resistance leading to patients poor overall survival. Finding those responsible mediators represents still an unmet medical need to reduce PCa mortality rate. Here we undertake an innovative translational approach to identify molecular cues underlying metastatic PCa.

We focus our attention on a poorly characterized cancer entity: castration-nave metastatic PCa , encompassing a tumor type that is metastatic at the time of first diagnosis. This tumor type is responsible for more than 50% of lethal PCa in the developed world. Through the project we will unleash prostate cancer vulnerabilities, to finally improve patient overall survival. For this reason, we built: PROSTarget

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Recerca Biomedica (irb Barcelona)BarcelonaSpainCoordinator
Universite Libre De BruxellesBruxellesBelgiumAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI